Oxidative brain damage in Mecp2-mutant murine models of Rett syndrome

Neurobiology of Disease

Volumn 68, Issue , 2014, Pages 66-77

  De Felice, Claudio ^a   Della Ragione, Floriana ^b,c   Signorini, Cinzia ^d   Leoncini, Silvia ^a,d   Pecorelli, Alessandra ^a,d   Ciccoli, Lucia ^d   Scalabrì, Francesco ^c   Marracino, Federico ^c   Madonna, Michele ^c   Belmonte, Giuseppe ^d   Ricceri, Laura ^e   De Filippis, Bianca ^e   Laviola, Giovanni ^e   Valacchi, Giuseppe ^f   Durand, Thierry ^g   Galano, Jean Marie ^g   Oger, Camille ^g   Guy, Alexandre ^g   Bultel Poncé, Valérie ^g   Guy, Jacky ^h   Filosa, Stefania ^b,c   Hayek, Joussef ^a   D'Esposito, Maurizio ^b,c   more..

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

^b INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^c IRCCS NEUROMED   (Italy)

^d UNIVERSITY OF SIENA   (Italy)

^e ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^f UNIVERSITY OF FERRARA   (Italy)

^g CNRS   (France)

^h UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Brain damage; Lipid peroxidation; Murine models; Neurodevelopmental disorder; Oxidative stress; Rett syndrome

Indexed keywords

4 HYDROXY 2 NONENAL PROTEIN ADDUCT; 4 HYDROXYNONENAL; BIOLOGICAL MARKER; F2 DIHOMOISOPROSTANE DERIVATIVE; F4 NEUROPROSTANE DERIVATIVE; GENOMIC DNA; IRON; ISOPROSTANE DERIVATIVE; METHYL CPG BINDING PROTEIN 2; NEUROPROSTANE; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG; 4-HYDROXY-2-NONENAL; ALDEHYDE; ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; MECP2 PROTEIN, MOUSE; NES PROTEIN, MOUSE; NESTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; CONTROLLED STUDY; FEMALE; GENE ACTIVATION; GENE MUTATION; LIPID PEROXIDATION; MALE; MECP2 GENE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RETT SYNDROME; SYMPTOM; WILD TYPE; ANALYSIS OF VARIANCE; ANIMAL; BLOOD; BRAIN INJURIES; C57BL MOUSE; COMPLICATION; DISEASE MODEL; GENETICS; MASS FRAGMENTOGRAPHY; METABOLISM; MUTATION; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

ALDEHYDES; ANALYSIS OF VARIANCE; ANIMALS; ARACHIDONIC ACID; BRAIN INJURIES; DISEASE MODELS, ANIMAL; DOCOSAHEXAENOIC ACIDS; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; ISOPROSTANES; MALE; METHYL-CPG-BINDING PROTEIN 2; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; NESTIN; NEUROPROSTANES; OXIDATIVE STRESS; RETT SYNDROME;

EID: 84899918808     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.04.006     Document Type: Article

References (76)

1. Amir R.E., Van den Veyver I.B., Wan M., Tran C.Q., Francke U., Zoghbi H.Y. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 1999, 23:185-188.
2. Bertulat B., De Bonis M.L., Della Ragione F., Lehmkuhl A., Milden M., Storm C., Jost K.L., Scala S., Hendrich B., D'Esposito M., Cardoso M.C. MeCP2 dependent heterochromatin reorganization during neural differentiation of a novel Mecp2-deficient embryonic stem cell reporter line. PLoS One 2012, 7:e47848.
3. Bienvenu T., Chelly J. Molecular genetics of Rett syndrome: when DNA methylation goes unrecognized. Nat. Rev. Genet. 2006, 7:415-426.
4. Buchovecky C.M., Turley S.D., Brown H.M., Kyle S.M., McDonald J.G., Liu B., Pieper A.A., Huang W., Katz D.M., Russell D.W., Shendure J., Justice M.J. A suppressor screen in Mecp2 mutant mice implicates cholesterol metabolism in Rett syndrome. Nat. Genet. 2013, 45:1013-1020.
5. Burford B., Kerr A.M., Macleod H.A. Nurse recognition of early deviation in development in home videos of infants with Rett disorder. J. Intellect. Disabil. Res. 2003, 47:588-596.
6. Calfa G., Percy A.K., Pozzo-Miller L. Experimental models of Rett syndrome based on Mecp2 dysfunction. Exp. Biol. Med. (Maywood) 2011, 236:3-19.
7. Chahrour M., Zoghbi H.Y. The story of Rett syndrome: from clinic to neurobiology. Neuron 2007, 56:422-437.
8. Chahrour M., Jung S.Y., Shaw C., Zhou X., Wong S.T., Qin J., Zoghbi H.Y. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 2008, 320:1224-1229.
9. Chen R.Z., Akbarian S., Tudor M., Jaenisch R. Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat. Genet. 2001, 27:327-331.
10. Cheung A.Y., Horvath L.M., Grafodatskaya D., Pasceri P., Weksberg R., Hotta A., Carrel L., Ellis J. Isolation of MECP2-null Rett syndrome patient hiPS cells and isogenic controls through X-chromosome inactivation. Hum. Mol. Genet. 2011, 20:2103-2115.
11. Ciccoli L., Leoncini S., Signorini C., Comporti M. Iron and erythrocytes: physiological and pathophysiological aspects. Oxidant in Biology: A Question of Balance 2008, 167-181. Springer. G. Valacchi, P. Davis (Eds.).
12. Dani V.S., Chang Q., Maffei A., Turrigiano G.G., Jaenisch R., Nelson S.B. Reduced cortical activity due to a shift in the balance between excitation and inhibition in a mouse model of Rett syndrome. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:12560-12565.
13. De Felice C., Ciccoli L., Leoncini S., Signorini C., Rossi M., Vannuccini L., Guazzi G., Latini G., Comporti M., Valacchi G., Hayek J. Systemic oxidative stress in classic Rett syndrome. Free Radic. Biol. Med. 2009, 47:440-448.
14. De Felice C., Guazzi G., Rossi M., Ciccoli L., Signorini C., Leoncini S., Tonni G., Latini G., Valacchi G., Hayek J. Unrecognized lung disease in classic Rett syndrome: a physiologic and high-resolution CT imaging study. Chest 2010, 138:386-392.
15. De Felice C., Signorini C., Durand T., Oger C., Guy A., Bultel-Ponce V., Galano J.M., Ciccoli L., Leoncini S., D'Esposito M., Filosa S., Pecorelli A., Valacchi G., Hayek J. F2-dihomo-isoprostanes as potential early biomarkers of lipid oxidative damage in Rett syndrome. J. Lipid Res. 2011, 52:2287-2297.
16. De Felice C., Signorini C., Durand T., Ciccoli L., Leoncini S., D'Esposito M., Filosa S., Oger C., Guy A., Bultel-Ponce V., Galano J.M., Pecorelli A., De Felice L., Valacchi G., Hayek J. Partial rescue of Rett syndrome by omega-3 polyunsaturated fatty acids (PUFAs) oil. Genes Nutr. 2012, 7:447-458.
17. De Felice C., Signorini C., Leoncini S., Pecorelli A., Durand T., Valacchi G., Ciccoli L., Hayek J. The role of oxidative stress in Rett syndrome: an overview. Ann. N. Y. Acad. Sci. 2012, 1259:121-135.
18. De Felice C., Signorini C., Leoncini S., Pecorelli A., Durand T., Galano J.M., Bultel-Poncé V., Guy A., Oger C., Zollo G., Valacchi G., Ciccoli L., Hayek J. Fatty acids and autism spectrum disorders: the Rett syndrome conundrum. Food Nutr. Sci. 2013, 71-75.
19. De Felice C., Rossi M., Leoncini S., Chisci G., Signorini C., Lonetti G., Vannuccini L., Spina D., Ginori A., Iacona I., Cortelazzo A., Pecorelli A., Valacchi G., Ciccoli L., Pizzorusso T., Hayek J. Inflammatory lung disease in Rett syndrome. Mediat. Inflamm. 2014, 2014:560120. 10.1155/2014/560120.
20. De Filippis B., Ricceri L., Laviola G. Early postnatal behavioral changes in the Mecp2-308 truncation mouse model of Rett syndrome. Genes Brain Behav. 2010, 9:213-223.
21. Delepine C., Nectoux J., Bahi-Buisson N., Chelly J., Bienvenu T. MeCP2 deficiency is associated with impaired microtubule stability. FEBS Lett. 2013, 587:245-253.
22. Derecki N.C., Cronk J.C., Lu Z., Xu E., Abbott S.B., Guyenet P.G., Kipnis J. Wild-type microglia arrest pathology in a mouse model of Rett syndrome. Nature 2012, 484:105-109.
23. Derecki N.C., Cronk J.C., Kipnis J. The role of microglia in brain maintenance: implications for Rett syndrome. Trends Immunol. 2013, 34:144-150.
24. Durand T., De Felice C., Signorini C., Oger C., Bultel-Ponce V., Guy A., Galano J.M., Leoncini S., Ciccoli L., Pecorelli A., Valacchi G., Hayek J. F(2)-dihomo-isoprostanes and brain white matter damage in stage 1 Rett syndrome. Biochimie 2013, 95:86-90.
25. Einspieler C., Kerr A.M., Prechtl H.F. Abnormal general movements in girls with Rett disorder: the first four months of life. Brain Dev. 2005, 27(Suppl. 1):S8-S13.
26. Einspieler C., Kerr A.M., Prechtl H.F. Is the early development of girls with Rett disorder really normal?. Pediatr. Res. 2005, 57:696-700.
27. Ferguson L.R. Chronic inflammation and mutagenesis. Mutat. Res. 2010, 690:3-11.
28. Galano J.M., Mas E., Barden A., Mori T.A., Signorini C., De Felice C., Barrett A., Opere C., Pinot E., Schwedhelm E., Benndorf R., Roy J., Le Guennec J.Y., Oger C., Durand T. Isoprostanes and neuroprostanes: total synthesis, biological activity and biomarkers of oxidative stress in humans. Prostaglandins Other Lipid Mediat. 2013, 107:95-102.
29. Garg S.K., Lioy D.T., Cheval H., McGann J.C., Bissonnette J.M., Murtha M.J., Foust K.D., Kaspar B.K., Bird A., Mandel G. Systemic delivery of MeCP2 rescues behavioral and cellular deficits in female mouse models of Rett syndrome. J. Neurosci. 2013, 33:13612-13620.
30. Goffin D., Allen M., Zhang L., Amorim M., Wang I.T., Reyes A.R., Mercado-Berton A., Ong C., Cohen S., Hu L., Blendy J.A., Carlson G.C., Siegel S.J., Greenberg M.E., Zhou Z. Rett syndrome mutation MeCP2 T158A disrupts DNA binding, protein stability and ERP responses. Nat. Neurosci. 2012, 15:274-283.
31. Grillo E., Lo Rizzo C., Bianciardi L., Bizzarri V., Baldassarri M., Spiga O., Furini S., De Felice C., Signorini C., Leoncini S., Pecorelli A., Ciccoli L., Mencarelli M.A., Hayek J., Meloni I., Ariani F., Mari F., Renieri A. Revealing the complexity of a monogenic disease: Rett syndrome exome sequencing. PLoS One 2013, 8:e56599.
32. Grosser E., Hirt U., Janc O.A., Menzfeld C., Fischer M., Kempkes B., Vogelgesang S., Manzke T.U., Opitz L., Salinas-Riester G., Muller M. Oxidative burden and mitochondrial dysfunction in a mouse model of Rett syndrome. Neurobiol. Dis. 2012, 48:102-114.
33. Guy J., Hendrich B., Holmes M., Martin J.E., Bird A. A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat. Genet. 2001, 27:322-326.
34. Guy J., Gan J., Selfridge J., Cobb S., Bird A. Reversal of neurological defects in a mouse model of Rett syndrome. Science 2007, 315:1143-1147.
35. Guy J., Cheval H., Selfridge J., Bird A. The role of MeCP2 in the brain. Annu. Rev. Cell Dev. Biol. 2011, 27:631-652.
36. Hagberg B. Clinical manifestations and stages of Rett syndrome. Ment. Retard. Dev. Disabil. Res. Rev. 2002, 8:61-65.
37. Halliwell B., Gutteridge J. Free Radicals in Biology and Medicine 2007, Oxford University Press. Fourth edition.
38. Han K., Gennarino V.A., Lee Y., Pang K., Hashimoto-Torii K., Choufani S., Raju C.S., Oldham M.C., Weksberg R., Rakic P., Liu Z., Zoghbi H.Y. Human-specific regulation of MeCP2 levels in fetal brains by microRNA miR-483-5p. Genes Dev. 2013, 27:485-490.
39. Janc O.A., Muller M. The free radical scavenger Trolox dampens neuronal hyperexcitability, reinstates synaptic plasticity, and improves hypoxia tolerance in a mouse model of Rett syndrome. Front. Cell. Neurosci. 2014, 8:56.
40. Jones P.L., Veenstra G.J., Wade P.A., Vermaak D., Kass S.U., Landsberger N., Strouboulis J., Wolffe A.P. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat. Genet. 1998, 19:187-191.
41. Katz D.M., Berger-Sweeney J.E., Eubanks J.H., Justice M.J., Neul J.L., Pozzo-Miller L., Blue M.E., Christian D., Crawley J.N., Giustetto M., Guy J., Howell C.J., Kron M., Nelson S.B., Samaco R.C., Schaevitz L.R., St Hillaire-Clarke C., Young J.L., Zoghbi H.Y., Mamounas L.A. Preclinical research in Rett syndrome: setting the foundation for translational success. Dis. Model Mech. 2012, 5:733-745.
42. Leonard H., Bower C. Is the girl with Rett syndrome normal at birth?. Dev. Med. Child Neurol. 1998, 40:115-121.
43. Leoncini S., De Felice C., Signorini C., Pecorelli A., Durand T., Valacchi G., Ciccoli L., Hayek J. Oxidative stress in Rett syndrome: natural history, genotype, and variants. Redox Rep. 2011, 16:145-153.
44. Lioy D.T., Garg S.K., Monaghan C.E., Raber J., Foust K.D., Kaspar B.K., Hirrlinger P.G., Kirchhoff F., Bissonnette J.M., Ballas N., Mandel G. A role for glia in the progression of Rett's syndrome. Nature 2011, 475:497-500.
45. Marschik P.B., Lanator I., Freilinger M., Prechtl H.F.R., Einspieler C. Early signs and later neurophysiological correlates of Rett syndrome. Klin. Neurophysiol. 2011, 42:22-26.
46. Moretti P., Bouwknecht J.A., Teague R., Paylor R., Zoghbi H.Y. Abnormalities of social interactions and home-cage behavior in a mouse model of Rett syndrome. Hum. Mol. Genet. 2005, 14:205-220.
47. Moretti P., Levenson J.M., Battaglia F., Atkinson R., Teague R., Antalffy B., Armstrong D., Arancio O., Sweatt J.D., Zoghbi H.Y. Learning and memory and synaptic plasticity are impaired in a mouse model of Rett syndrome. J. Neurosci. 2006, 26:319-327.
48. Nagy G., Ackerman S.L. Cholesterol metabolism and Rett syndrome pathogenesis. Nat. Genet. 2013, 45:965-967.
49. Neul J.L., Kaufmann W.E., Glaze D.G., Christodoulou J., Clarke A.J., Bahi-Buisson N., Leonard H., Bailey M.E., Schanen N.C., Zappella M., Renieri A., Huppke P., Percy A.K. Rett syndrome: revised diagnostic criteria and nomenclature. Ann. Neurol. 2010, 68:944-950.
50. Panayotis N., Pratte M., Borges-Correia A., Ghata A., Villard L., Roux J.C. Morphological and functional alterations in the substantia nigra pars compacta of the Mecp2-null mouse. Neurobiol. Dis. 2011, 41:385-397.
51. Pecorelli A., Ciccoli L., Signorini C., Leoncini S., Giardini A., D'Esposito M., Filosa S., Hayek J., De Felice C., Valacchi G. Increased levels of 4HNE-protein plasma adducts in Rett syndrome. Clin. Biochem. 2011, 44:368-371.
52. Pecorelli A., Leoncini S., De Felice C., Signorini C., Cerrone C., Valacchi G., Ciccoli L., Hayek J. Non-protein-bound iron and 4-hydroxynonenal protein adducts in classic autism. Brain Dev. 2013, 35:146-154.
53. Picker J.D., Yang R., Ricceri L., Berger-Sweeney J. An altered neonatal behavioral phenotype in Mecp2 mutant mice. Neuroreport 2006, 17:541-544.
54. Poli G., Schaur R.J., Siems W.G., Leonarduzzi G. 4-Hydroxynonenal: a membrane lipid oxidation product of medicinal interest. Med. Res. Rev. 2008, 28:569-631.
55. Praticò D. The neurobiology of isoprostanes and Alzheimer's disease. Biochim. Biophys. Acta 2010, 1801:930-933.
56. Ramirez J.M., Ward C.S., Neul J.L. Breathing challenges in Rett syndrome: lessons learned from humans and animal models. Respir. Physiol. Neurobiol. 2013, 189:280-287.
57. Rett A. On a unusual brain atrophy syndrome in hyperammonemia in childhood. Wien. Med. Wochenschr. 1966, 116:723-726.
58. Ricceri L., De Filippis B., Laviola G. Mouse models of Rett syndrome: from behavioural phenotyping to preclinical evaluation of new therapeutic approaches. Behav. Pharmacol. 2008, 19:501-517.
59. Robinson L., Guy J., McKay L., Brockett E., Spike R.C., Selfridge J., De Sousa D., Merusi C., Riedel G., Bird A., Cobb S.R. Morphological and functional reversal of phenotypes in a mouse model of Rett syndrome. Brain 2012, 135:2699-2710.
60. Rouault T.A. Iron metabolism in the CNS: implications for neurodegenerative diseases. Nat. Rev. Neurosci. 2013, 14:551-564.
61. Santos M., Silva-Fernandes A., Oliveira P., Sousa N., Maciel P. Evidence for abnormal early development in a mouse model of Rett syndrome. Genes Brain Behav. 2007, 6:277-286.
62. Schroder N., Figueiredo L.S., de Lima M.N. Role of brain iron accumulation in cognitive dysfunction: evidence from animal models and human studies. J. Alzheimer's Dis. 2013, 34:797-812.
63. Shahbazian M., Young J., Yuva-Paylor L., Spencer C., Antalffy B., Noebels J., Armstrong D., Paylor R., Zoghbi H. Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3. Neuron 2002, 35:243-254.
64. Sierra C., Vilaseca M.A., Brandi N., Artuch R., Mira A., Nieto M., Pineda M. Oxidative stress in Rett syndrome. Brain Dev. 2001, 23(Suppl. 1):S236-S239.
65. Signorini C., Comporti M., Giorgi G. Ion trap tandem mass spectrometric determination of F2-isoprostanes. J. Mass Spectrom. 2003, 38:1067-1074.
66. Signorini C., Ciccoli L., Leoncini S., Carloni S., Perrone S., Comporti M., Balduini W., Buonocore G. Free iron, total F-isoprostanes and total F-neuroprostanes in a model of neonatal hypoxic-ischemic encephalopathy: neuroprotective effect of melatonin. J. Pineal Res. 2009, 46:148-154.
67. Signorini C., De Felice C., Leoncini S., Giardini A., D'Esposito M., Filosa S., Della Ragione F., Rossi M., Pecorelli A., Valacchi G., Ciccoli L., Hayek J. F(4)-neuroprostanes mediate neurological severity in Rett syndrome. Clin. Chim. Acta 2011, 412:1399-1406.
68. Signorini C., De Felice C., Durand T., Oger C., Galano J.M., Leoncini S., Pecorelli A., Valacchi G., Ciccoli L., Hayek J. Isoprostanes and 4-hydroxy-2-nonenal: markers or mediators of disease? Focus on Rett syndrome as a model of autism spectrum disorder. Oxid. Med. Cell. Longev. 2013, 2013:343824.
69. Singh M., Dang T.N., Arseneault M., Ramassamy C. Role of by-products of lipid oxidation in Alzheimer's disease brain: a focus on acrolein. J. Alzheimer's Dis. 2010, 21:741-756.
70. Sticozzi C., Belmonte G., Pecorelli A., Cervellati F., Leoncini S., Signorini C., Ciccoli L., De Felice C., Hayek J., Valacchi G. Scavenger receptor B1 post-translational modifications in Rett syndrome. FEBS Lett. 2013, 587:2199-2204.
71. Temudo T., Maciel P., Sequeiros J. Abnormal movements in Rett syndrome are present before the regression period: a case study. Mov. Disord. 2007, 22:2284-2287.
72. Tronche F., Kellendonk C., Kretz O., Gass P., Anlag K., Orban P.C., Bock R., Klein R., Schutz G. Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. Nat. Genet. 1999, 23:99-103.
73. Valacchi G., Pecorelli A., Signorini C., Leoncini S., Ciccoli L., De Felice C., Hayek J. 4HNE protein adducts in autistic spectrum disorders: Rett syndrome and autism. Comprehensive Guide to Autism 2014, 2667-2688. Springer, New York. V.B. Patel, P.V.R., C.R. Martin (Eds.).
74. Weaving L.S., Ellaway C.J., Gecz J., Christodoulou J. Rett syndrome: clinical review and genetic update. J. Med. Genet. 2005, 42:1-7.
75. Yazdani M., Deogracias R., Guy J., Poot R.A., Bird A., Barde Y.A. Disease modeling using embryonic stem cells: MeCP2 regulates nuclear size and RNA synthesis in neurons. Stem Cells 2012, 30:2128-2139.
76. Zachariah R.M., Olson C.O., Ezeonwuka C., Rastegar M. Novel MeCP2 isoform-specific antibody reveals the endogenous MeCP2E1 expression in murine brain, primary neurons and astrocytes. PLoS One 2012, 7:e49763.